Cutting Edge: Hyperinflammatory Monocytes Expressing CD56 Abound in Severe COVID-19 Patients.
Stefania CampanaClaudia De PasqualeGiacomo Sidoti MiglioreGaetana PezzinoRiccardo CavaliereEmmanuele Venanzi RulloGiuseppe NunnariGaetano CaramoriAntonio DavidIrene BonaccorsiTeresa PollicinoPaolo CarregaGuido FerlazzoPublished in: Journal of immunology (Baltimore, Md. : 1950) (2022)
Proinflammatory monocytes play a preponderant role in the development of a cytokine storm causing fatal consequences in coronavirus disease 2019 (COVID-19) patients, highlighting the importance of analyzing in more detail monocyte distribution in these patients. In this study, we identified an atypical monocyte subpopulation expressing CD56 molecules that showed a low level of HLA-DR and high level of l-selectin. They released higher amounts of TNF-α and IL-6 and expressed genes associated with an excessive inflammatory process. Remarkably, the frequency of CD56 + monocytes inversely correlated with that of CD16 + monocytes and a high CD56 + /CD16 + monocyte ratio was associated with both disease severity and mortality, as well as with serum concentration of type I IFN, a factor able to induce the appearance of CD56 + monocytes. In conclusion, severe COVID-19 is characterized by the abundance of hyperinflammatory CD56 + monocytes, which could represent a novel marker with prognostic significance and, possibly, a therapeutic target for controlling the inflammatory process occurring during COVID-19.